Compare RCAT & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCAT | XNCR |
|---|---|---|
| Founded | 2002 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2017 | 2013 |
| Metric | RCAT | XNCR |
|---|---|---|
| Price | $10.35 | $23.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $20.00 | ★ $22.33 |
| AVG Volume (30 Days) | ★ 8.4M | 1.1M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | $17,836,382.00 | ★ $125,576,000.00 |
| Revenue This Year | $271.60 | N/A |
| Revenue Next Year | $41.21 | $4.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 79.95 | 13.65 |
| 52 Week Low | $5.77 | $7.13 |
| 52 Week High | $18.78 | $22.22 |
| Indicator | RCAT | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 61.78 | 74.17 |
| Support Level | $7.16 | $11.05 |
| Resistance Level | $11.74 | N/A |
| Average True Range (ATR) | 0.70 | 1.29 |
| MACD | 0.42 | 0.11 |
| Stochastic Oscillator | 86.19 | 99.05 |
Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Its suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities. The firm's Division includes Teal, FlightWave, and Blue Ops.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.